We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mgi Pharma (MM) | NASDAQ:MOGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Amendment No. 3)
SOLICITATION/RECOMMENDATION STATEMENT UNDER
SECTION 14(d)(4) OF THE SECURITIES EXCHANGE
ACT OF 1934
MGI PHARMA, INC.
(Name of Subject Company)
MGI PHARMA, INC.
(Name of Persons Filing Statement)
Common Stock, Par Value $0.01 per share
(including the associated preferred stock purchase rights)
(Title of Class of Securities)
552880106
(CUSIP Number of Class of Securities)
E ric P. Loukas
Executive Vice President, Chief Operating Officer,
General Counsel and Corporate Secretary
MGI PHARMA, INC.
5775 West Old Shakopee Road, Suite 100
Bloomington, Minnesota 55437-3174
(952) 346-4700
(Name, address and telephone numbers of person authorized to receive notice and
communications on behalf of the persons filing statement)
Copies to:
Asher M. Rubin
Glenn C. Campbell
William I. Intner
Hogan &
Hartson L.L.P.
111 S. Calvert Street Suite 1600
Baltimore, Maryland 21202
(410) 659-2700
o |
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
This Amendment No. 3 amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 filed on December 21, 2007 (as previously amended and supplemented by Amendment No. 1 on January 4, 2008 and Amendment No. 2 on January 11, 2008, the Schedule 14D-9) with the Securities and Exchange Commission (the SEC) by MGI PHARMA, INC., a Minnesota corporation (the Company). The Schedule 14D-9 relates to the offer by Jaguar Acquisition Corp. (Offeror), a Minnesota corporation and an indirect wholly-owned subsidiary of Eisai Co., Ltd., a corporation organized under the laws of Japan (Parent), to purchase all of the issued and outstanding shares of common stock, par value $0.01 per share, of the Company (including the associated rights to purchase Series A Junior Participating Preferred Stock of the Company, the Shares) at a purchase price of $41.00 per Share, net to the holder thereof in cash, without interest and subject to the applicable withholding of taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated December 21, 2007, as amended or supplemented from time to time, and the related Letter of Transmittal.
Except as otherwise indicated, the information set forth in the Schedule 14D-9 remains unchanged. Capitalized terms used, but not defined, in this Amendment No. 3 have the meanings ascribed to them in the Schedule 14D-9.
Item 8. Additional Information.
Item 8 is hereby amended and supplemented to add the following paragraph as the last paragraph under the heading Antitrust:
On Wednesday, January 16, 2008, the Federal Trade Commission granted early termination of the statutory waiting period under the HSR Act applicable to the Offer. The grant of early termination of the waiting period satisfies one of the conditions of the Offer.
Item 9. Exhibits.
Item 9 of the Schedule 14D-9 is hereby amended and supplemented as follows:
Exhibit No. |
|
Description |
(a)(1)(A) |
|
Offer to Purchase,
dated December 21, 2007 (incorporated by reference to Exhibit (a)(1) to
the
|
|
|
|
(a)(1)(B) |
|
Letter of Transmittal
(including Guidelines for Certification of Taxpayer Identification Number
|
|
|
|
(a)(1)(C) |
|
Notice of Guaranteed Delivery (incorporated by reference to Exhibit (a)(3) to the Schedule TO). |
|
|
|
(a)(1)(D) |
|
Letter to Brokers, Dealers,
Commercial Banks, Trust Companies and Other Nominees (incorporated
|
|
|
|
(a)(1)(E) |
|
Letter to Clients for
use by Brokers, Dealers, Commercial Banks, Trust Companies and
|
|
|
|
(a)(1)(F) |
|
Press Release issued by
Company on November 29, 2007 announcing that it was exploring possible
|
|
|
|
(a)(1)(G) |
|
Press Release issued by
Parent and the Company on December 10, 2007 (incorporated by reference
|
|
|
|
(a)(1)(H) |
|
Information Statement
Pursuant to Section 14(f) of the Securities Exchange Act of 1934 and Rule
|
|
|
|
(a)(1)(I) |
|
MGI PHARMA, INC. Employment and Benefit Q&As.* |
|
|
|
(a)(1)(J) |
|
Press Release issued by
the Company and Parent on January 17, 2008 announcing the early
|
|
|
|
(a)(2) |
|
Letter to Shareholders
from the President and Chief Executive Officer of MGI PHARMA, INC.,
|
|
|
|
(a)(5)(A) |
|
Opinion of Lehman
Brothers, Inc. to the Board of Directors of MGI PHARMA, INC., dated
|
|
|
|
(a)(5)(B) |
|
Complaint filed by L.A.
Murphy in the Fourth Judicial District Court of the State of Minnesota,
|
|
|
|
(a)(5)(C) |
|
Complaint filed by
Judith Dreyer in the Fourth Judicial District Court of the State of
Minnesota,
|
|
|
|
(e)(1) |
|
Agreement and Plan of
Merger, dated December 10, 2007, between MGI PHARMA, INC., a
|
|
|
|
(e)(2) |
|
Form of Termination
Agreement, between MGI PHARMA, INC. and each of its Executive Officers
|
|
|
|
(e)(3) |
|
Retention Agreement,
dated December 15, 2007, between Leon O. Moulder, Jr. and Eisai
|
2
|
|
Corporation of North America.* |
|
|
|
(e)(4) |
|
Retention Agreement,
dated December 15, 2007, between Mary Lynne Hedley and Eisai
|
|
|
|
(e)(5) |
|
Confidentiality
Agreement, dated September 27, 2007, between MGI PHARMA, INC. and
Eisai
|
|
|
|
(e)(6) |
|
Amendment No. 2 to
Rights Agreement, dated December 20, 2007, to the Rights Agreement,
dated
|
* Previously filed.
** Filed herewith
3
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
MGI PHARMA, INC. |
|
||
Date: January 17, 2008 |
|
By: |
/s/ Eric P. Loukas |
||
|
|
Name: |
Eric P. Loukas |
||
|
|
Title: |
Executive Vice President, Chief Operating Officer, General Counsel and Corporate Secretary |
||
4
1 Year Mgi Pharma (MM) Chart |
1 Month Mgi Pharma (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions